{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T17:24:50Z","timestamp":1787765090548,"version":"build-2784847793"},"reference-count":36,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","funder":[{"name":"Clinigen Inc.","award":["CIIT19PLK02"],"award-info":[{"award-number":["CIIT19PLK02"]}]}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,10]]},"abstract":"<jats:p>To assess the combination of high dose interleukin 2 (HD IL2) and nivolumab in patients with checkpoint inhibitor-refractory melanoma or renal cell carcinoma (RCC), we performed a single-arm, Simon two-stage phase II trial for patients with unresectable stage III or IV melanoma or any histology RCC. The primary endpoint was overall response rate (ORR); secondary endpoints were adverse events and progression-free survival (PFS), defined as time to radiographic or clinical progression, whichever occurred first. Five patients enrolled, three with melanoma and two with RCC. Median age at registration was 47 (35\u201377) years. Two patients (40%) had treated or asymptomatic brain metastases, and one (20%) had liver metastases. Median prior lines of systemic therapy per patient were 3 (2\u20135). Patients completed a median of 1 (0.5\u20133) treatment cycle, involving two admissions for HD IL2 administration and two doses of nivolumab. ORR was 20%. Median PFS was 1.4 (0.8\u201345.0) months. Time to next therapy for each living patient was 2.5 and 45.6 months for local modalities, and 2.0, 2.3, and 45.9 months for systemic therapies. Adverse events reflected the known toxicity of HD IL2. One treatment-related death occurred, leading to trial termination. The combination of HD IL2 and nivolumab resulted in a durable response in one of five patients with PD-1-refractory advanced melanoma or RCC. Use of HD IL2 remains limited by its toxicity; augmented IL2 formulations and administration strategies are needed. ClinicalTrials.gov ID: NCT03889782 (Registered 6\/16\/2019; https:\/\/clinicaltrials.gov\/study\/NCT03889782).<\/jats:p>","DOI":"10.1097\/cmr.0000000000001102","type":"journal-article","created":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T03:00:15Z","timestamp":1777863615000},"page":"444-452","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["High dose interleukin-2 in combination with anti-programmed cell death protein 1 to overcome immune checkpoint inhibitor resistance in metastatic melanoma and renal cell carcinoma"],"prefix":"10.1097","volume":"36","author":[{"given":"Tali","family":"Azenkot","sequence":"first","affiliation":[{"name":"Moores Cancer Center, University of California, San Diego, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mina","family":"Nikanjam","sequence":"additional","affiliation":[{"name":"Moores Cancer Center, University of California, San Diego, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soham","family":"Mhatre","sequence":"additional","affiliation":[{"name":"Moores Cancer Center, University of California, San Diego, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaren T.","family":"Mullen","sequence":"additional","affiliation":[{"name":"University of Miami Miller School of Medicine, Miami, Florida"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donald A.","family":"Barkauskas","sequence":"additional","affiliation":[{"name":"Department of Population and Public Health Sciences, Keck School of Medicine of the University of Southern California, Los Angeles, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rana R.","family":"McKay","sequence":"additional","affiliation":[{"name":"Moores Cancer Center, University of California, San Diego, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joel M.","family":"Baumgartner","sequence":"additional","affiliation":[{"name":"Moores Cancer Center, University of California, San Diego, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory A.","family":"Daniels","sequence":"additional","affiliation":[{"name":"Moores Cancer Center, University of California, San Diego, California"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,4,30]]},"reference":[{"key":"R1-20260826","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJMoa1504030","article-title":"Combined nivolumab and ipilimumab or monotherapy in untreated melanoma.","volume":"373","author":"Larkin","year":"2015","journal-title":"N Engl J Med"},{"key":"R2-20260826","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1056\/NEJMoa1712126","article-title":"Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma.","volume":"378","author":"Motzer","year":"2018","journal-title":"N Engl J Med"},{"key":"R3-20260826","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1097\/00000658-199809000-00004","article-title":"Durability of complete responses in patients with metastatic cancer treated with high-dose interleukin-2: identification of the antigens mediating response.","volume":"228","author":"Rosenberg","year":"1998","journal-title":"Ann Surg"},{"key":"R4-20260826","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1007\/s00262-016-1910-x","article-title":"Contemporary experience with high-dose interleukin-2 therapy and impact on survival in patients with metastatic melanoma and metastatic renal cell carcinoma.","volume":"65","author":"Alva","year":"2016","journal-title":"Cancer Immunol Immunother"},{"key":"R5-20260826","doi-asserted-by":"crossref","first-page":"4756","DOI":"10.1200\/JCO.23.00172","article-title":"Bempegaldesleukin plus nivolumab in untreated advanced melanoma: the open-label, phase III PIVOT IO 001 trial results.","volume":"41","author":"Diab","year":"2023","journal-title":"J Clin Oncol"},{"key":"R6-20260826","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s40425-014-0026-0","article-title":"High dose interleukin-2 (Aldesleukin) \u2013 expert consensus on best management practices-2014.","volume":"2","author":"Dutcher","year":"2014","journal-title":"J ImmunoTher Cancer"},{"key":"R7-20260826","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1097\/00002371-200107000-00004","article-title":"Guidelines for the safe administration of high-dose interleukin-2.","volume":"24","author":"Schwartzentruber","year":"2001","journal-title":"J Immunother"},{"key":"R8-20260826","doi-asserted-by":"crossref","first-page":"2604","DOI":"10.1172\/JCI67008","article-title":"PD-L1 blockade synergizes with IL-2 therapy in reinvigorating exhausted T cells.","volume":"123","author":"West","year":"2013","journal-title":"J Clin Invest"},{"key":"R9-20260826","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1038\/s41586-022-05257-0","article-title":"PD-1 combination therapy with IL-2 modifies CD8+ T cell exhaustion program.","volume":"610","author":"Hashimoto","year":"2022","journal-title":"Nature"},{"key":"R10-20260826","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/s40425-019-0522-3","article-title":"Therapy with high-dose Interleukin-2 (HD IL-2) in metastatic melanoma and renal cell carcinoma following PD1 or PDL1 inhibition.","volume":"7","author":"Buchbinder","year":"2019","journal-title":"J ImmunoTher Cancer"},{"key":"R11-20260826","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1186\/s13256-022-03536-y","article-title":"Combination high-dose interleukin-2 and nivolumab for programmed cell death-1 refractory metastatic melanoma: a case series.","volume":"16","author":"Nikanjam","year":"2022","journal-title":"J Med Case Rep"},{"key":"R13-20260826","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"R15-20260826","doi-asserted-by":"crossref","first-page":"2500","DOI":"10.1056\/NEJMc1713444","article-title":"Tumor mutational burden and response rate to PD-1 inhibition.","volume":"377","author":"Yarchoan","year":"2017","journal-title":"N Engl J Med"},{"key":"R16-20260826","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1200\/jco.2014.32.4_suppl.430","article-title":"High-dose interleukin-2 registry, PROCLAIM: modern data on toxicities and outcomes.","volume":"32","author":"Lowder","year":"2014","journal-title":"J Clin Oncol"},{"key":"R17-20260826","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1200\/JCO.1995.13.3.688","article-title":"Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy.","volume":"13","author":"Fyfe","year":"1995","journal-title":"J Clin Oncol"},{"key":"R18-20260826","first-page":"S11","article-title":"High-dose recombinant interleukin-2 therapy in patients with metastatic melanoma: long-term survival update.","volume":"6","author":"Atkins","year":"2000","journal-title":"Cancer J Sci Am"},{"key":"R19-20260826","doi-asserted-by":"crossref","first-page":"e011119","DOI":"10.1136\/jitc-2024-011119","article-title":"Role of high-dose interleukin-2 for melanoma in the age of cellular therapy.","volume":"13","author":"Buchbinder","year":"2025","journal-title":"J ImmunoTher Cancer"},{"key":"R22-20260826","doi-asserted-by":"crossref","first-page":"e010143","DOI":"10.1136\/jitc-2024-010143","article-title":"Nemvaleukin alfa, a modified interleukin-2 cytokine, as monotherapy and with pembrolizumab in patients with advanced solid tumors (ARTISTRY-1).","volume":"12","author":"Vaishampayan","year":"2024","journal-title":"J ImmunoTher Cancer"},{"key":"R23-20260826","doi-asserted-by":"crossref","first-page":"2595","DOI":"10.1200\/JCO.2024.42.16_suppl.2595","article-title":"Phase 1\/2 study of XTX202, a tumor-activated IL-2\u03b2\u03b3, in advanced solid tumors.","volume":"42","author":"Chahoud","year":"2024","journal-title":"J Clin Oncol"},{"key":"R24-20260826","doi-asserted-by":"crossref","first-page":"TPS9599","DOI":"10.1200\/JCO.2023.41.16_suppl.TPS9599","article-title":"OMNIA-1: a phase I\/II study, an IL-2R-\u03b2\u03b3 targeted antibody-IL-2 fusion protein, as monotherapy or in combination with anti-PD-1 or anti-CTLA-4 antibodies, in patients with advanced melanoma.","volume":"41","author":"Ascierto","year":"2023","journal-title":"J Clin Oncol"},{"key":"R25-20260826","doi-asserted-by":"crossref","first-page":"2601","DOI":"10.1200\/JCO.2024.42.16_suppl.2601","article-title":"TransCon IL-2 \u03b2\/\u03b3 alone or in combination with pembrolizumab, standard of care chemotherapy or TransCon TLR7\/8 agonist in advanced\/metastatic solid tumors: updated results of the phase 1\/2 IL Believe study.","volume":"42","author":"Starodub","year":"2024","journal-title":"J Clin Oncol"},{"key":"R26-20260826","doi-asserted-by":"crossref","first-page":"2623","DOI":"10.1200\/JCO.2024.42.16_suppl.2623","article-title":"A phase 1\/1b study of the IL-2 prodrug WTX-124 in patients with locally advanced or metastatic solid tumors after checkpoint inhibitor therapy: initial results of the combination dose escalation with pembrolizumab.","volume":"42","author":"Moser","year":"2024","journal-title":"J Clin Oncol"},{"key":"R27-20260826","doi-asserted-by":"crossref","first-page":"2598","DOI":"10.1200\/JCO.2024.42.16_suppl.2598","article-title":"A first-in-human, phase 1\/2a study of GI-102 (CD80-IL2v3) in patients with advanced or metastatic solid tumors: initial results from dose escalation.","volume":"42","author":"Lee","year":"2024","journal-title":"J Clin Oncol"},{"key":"R28-20260826","doi-asserted-by":"crossref","first-page":"2502","DOI":"10.1200\/JCO.2025.43.16_suppl.2502","article-title":"Efficacy and safety results of a first-in-class PD-1\/IL-2\u03b1-bias bispecific antibody fusion protein IBI363 in patients (pts) with immunotherapy-treated, advanced acral and mucosal melanoma.","volume":"43","author":"Lian","year":"2025","journal-title":"J Clin Oncol"},{"key":"R29-20260826","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1200\/JCO.2025.43.16_suppl.104","article-title":"Efficacy and safety of IBI363 monotherapy or in combination with bevacizumab in patients with advanced colorectal cancer.","volume":"43","author":"Lin","year":"2025","journal-title":"J Clin Oncol"},{"key":"R30-20260826","doi-asserted-by":"crossref","first-page":"8509","DOI":"10.1200\/JCO.2025.43.16_suppl.8509","article-title":"First-in-class PD-1\/IL-2 bispecific antibody IBI363 in patients (Pts) with advanced immunotherapy-treated non-small cell lung cancer (NSCLC).","volume":"43","author":"Zhou","year":"2025","journal-title":"J Clin Oncol"},{"key":"R32-20260826","doi-asserted-by":"crossref","first-page":"e003155","DOI":"10.1136\/jitc-2021-003155","article-title":"Fine-tuned long-acting interleukin-2 superkine potentiates durable immune responses in mice and non-human primate.","volume":"10","author":"Merchant","year":"2022","journal-title":"J ImmunoTher Cancer"},{"key":"R34-20260826","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.3389\/fonc.2019.01483","article-title":"High-dose ipilimumab and high-dose interleukin-2 for patients with advanced melanoma.","volume":"9","author":"Silk","year":"2019","journal-title":"Front Oncol"},{"key":"R35-20260826","doi-asserted-by":"crossref","first-page":"9543","DOI":"10.1200\/JCO.2024.42.16_suppl.9543","article-title":"High dose bolus (HDB) interleukin-2 (IL2) and concurrent low dose ipilimumab followed sequentially by nivolumab in patients with advanced melanoma after failure of anti-PD1-based immunotherapy and BRAF-MEK inhibition.","volume":"42","author":"Tarhini","year":"2024","journal-title":"J Clin Oncol"},{"key":"R36-20260826","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1186\/s40425-018-0387-x","article-title":"A multi-center phase II study of high dose interleukin-2 sequenced with vemurafenib in patients with BRAF-V600 mutation positive metastatic melanoma.","volume":"6","author":"Clark","year":"2018","journal-title":"J ImmunoTher Cancer"},{"key":"R37-20260826","doi-asserted-by":"crossref","first-page":"e1423172","DOI":"10.1080\/2162402X.2017.1423172","article-title":"A phase II study of combined therapy with a BRAF inhibitor (vemurafenib) and interleukin-2 (aldesleukin) in patients with metastatic melanoma.","volume":"7","author":"Mooradian","year":"2018","journal-title":"Oncoimmunology"},{"key":"R38-20260826","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.clgc.2022.01.010","article-title":"Coordinated pembrolizumab and high dose IL-2 (5-in-a-row schedule) for therapy of metastatic clear cell renal cancer.","volume":"20","author":"Chatzkel","year":"2022","journal-title":"Clin Genitourin Cancer"},{"key":"R39-20260826","doi-asserted-by":"crossref","first-page":"1108341","DOI":"10.3389\/fonc.2023.1108341","article-title":"A phase Ib study of interleukin-2 plus pembrolizumab for patients with advanced melanoma.","volume":"13","author":"Silk","year":"2023","journal-title":"Front Oncol"},{"key":"R40-20260826","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1016\/S1470-2045(21)00097-8","article-title":"Ipilimumab alone or ipilimumab plus anti-PD-1 therapy in patients with metastatic melanoma resistant to anti-PD-(L)1 monotherapy: a multicentre, retrospective, cohort study.","volume":"22","author":"Pires da Silva","year":"2021","journal-title":"Lancet Oncol"},{"key":"R41-20260826","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1200\/OP-24-00875","article-title":"Recent developments in the management of renal cell cancer.","volume":"21","author":"Chen","year":"2025","journal-title":"JCO Oncol Pract"},{"key":"R42-20260826","doi-asserted-by":"crossref","first-page":"P67","DOI":"10.1186\/2051-1426-1-S1-P67","article-title":"High dose interleukin-2 registry, PROCLAIMTM; higher center-specific IL-2 dose density correlates with higher response rates.","volume":"1","author":"Wong","year":"2013","journal-title":"J ImmunoTher Cancer"}],"container-title":["Melanoma Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/CMR.0000000000001102","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T17:01:17Z","timestamp":1787763677000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/CMR.0000000000001102"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,30]]},"references-count":36,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/cmr.0000000000001102","relation":{},"ISSN":["0960-8931","1473-5636"],"issn-type":[{"value":"0960-8931","type":"print"},{"value":"1473-5636","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,30]]},"assertion":[{"value":"2026-02-04","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-04-13","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}